Clinical Trial Update: A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2a open-label study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of YOLT-201 in patients with transthyretin amyloidosis po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloidosis Cardiomyopathy
• Transthyretin Amyloidosis Polyneuropathy

Drugs mentioned

• YOLT-201

Snippet

Sponsor: YolTech Therapeutics Co., Ltd | Conditions: Transthyretin Amyloidosis Polyneuropathy, Transthyrexin Amyloidosis Cardiomyopathy | Phase 1, Phase 2 | Status: RECRUITING